Bisphosphonate-related osteonecrosis of the skull base.
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is reported in up to 18.6% of patients treated with intravenous bisphosphonates and can result in significant morbidity. Most cases are managed by oral surgeons with only a handful of reports appearing in the otolaryngology literature. We present a unique case of extensive BRONJ involving the maxilla, sinuses, and skull base, complicated by sinusitis and an intracranial abscess. This is the first description of BRONJ involving the skull base. The pathogenesis and management of this process are reviewed.
Khan
Aayesha M
AM
Department of Otolaryngology-Head and Neck Surgery, Saint Louis University School of Medicine, St Louis, Missouri 63110, USA.
Sindwani
Raj
R
D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D019635:Neurosurgical Procedures / Q000379:methods; D010020:Osteonecrosis / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000601:surgery; D019291:Skull Base / Q000000981:diagnostic imaging / Q000187:drug effects*; D014057:Tomography, X-Ray Computed / Q000379:methods*; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid